Despite significant advances over the past decades, very few Tissue Engineered Medical Products (TEMPs) have been clinically and/or commercially successful so far.  However, the need for TEMPs is rapidly growing along with the expanding applications, thus generating a severe technology gap. What is often described as  “the Valley of Death”, that new technologies emerging out of laboratories have to traverse to becoming clinically relevant, and commercially viable, requires tailored measures. The development of  scalable, consistent and cost-effective manufacturing processes of TEMPs is one of the big challenges of this century.

Thus, CM²OST main aims are:  (1) to bridge the existing technology gap and (2) to enable a faster path to market for TEMPs. By developing novel technologies at CWRU in the research laboratories, by demonstrating and deploying them into a “biofoundry line”, modelled at and reinforced by ARMI which is based on Quality-by-Design approaches, the center will  significantly facilitate the manufacture of a variety of structural tissues. Our ultimate objective is to promote our new technologies and wrap-around approach for adoption by the “TEMP Community” at large.